In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates

Commentary on: Lonn EM, Bosch J, López-Jaramillo P, et al.. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2009–20 . Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2021–31. Context Cardiovascular diseases (CVD) are the number one cause of death globally: more people die annually from CVDs than from any other cause.1 The incidence of CVD rises progressively with increasing blood pressure (BP) and with increasing levels of total and low density lipoprotein (LDL) cholesterol. Pharmacological treatment of BP with several classes of drugs and of lipids with HMG-CoA reductase inhibitors (statins) have been demonstrated to reduce the incidence of CVD.2 3 Antihypertensive trials have predominantly enrolled individuals at specific BP levels and titrated medications to achieve either a specific target BP or a specific decrease...
Source: Evidence-Based Medicine - Category: Internal Medicine Authors: Tags: Drugs: cardiovascular system, Pain (neurology), Stroke, Hypertension, Ischaemic heart disease Therapeutics/Prevention Source Type: research